Cardiol Therapeutics Inc.
CRDLHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Cardiol Therapeutics Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. With a market capitalization of $257.0M, it sits in micro-cap territory. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Market Cap
$257.0M
Beta
0.61
P/E (TTM)
—
P/E (Fwd)
-9.17
EPS (TTM)
$-0.25
EPS (Fwd)
$-0.24
ROE
-190.2%
ROA
-90.9%
Cash
$26.1M
Total Debt
$106,998
Free CF
-$15.5M
52W Change
113.6%
Annual Financials
Cash vs Debt
Where CRDL stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CRDL finished 72.22% above its 150-day moving average ($1.26) and 82.35% above its 200-day moving average ($1.19). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CRDL overbought or oversold?
At the September 3, 2026 close, CRDL's RSI(14) was 71.7, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Cardiol Therapeutics Inc. holds $26.1M in cash against $107K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$15.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -190.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
CRDL's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, CRDL has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing CRDL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.